Abstract

A group of cytotoxic half-sandwich iridium(III) complexes with aminomethyl(diphenyl)phosphine derived from fluoroquinolone antibiotics exhibit the ability to (i) accumulate in the nucleus, (ii) induce apoptosis, (iii) activate caspase-3/7 activity, (iv) induce the changes in cell cycle leading to G2/M phase arrest, and (v) radicals generation. Herein, to elucidate the cytotoxic effects, we investigated the interaction of these complexes with DNA and serum proteins by gel electrophoresis, fluorescence spectroscopy, circular dichroism, and molecular docking studies. DNA binding experiments established that the complexes interact with DNA by moderate intercalation and predominance of minor groove binding without the capability to cause a double-strand cleavage. The molecular docking study confirmed two binding modes: minor groove binding and threading intercalation with the fluoroquinolone part of the molecule involved in pi stacking interactions and the Ir(III)-containing region positioned within the major or minor groove. Fluorescence spectroscopic data (HSA and apo-Tf titration), together with molecular docking, provided evidence that Ir(III) complexes can bind to the proteins in order to be transferred. All the compounds considered herein were found to bind to the tryptophan residues of HSA within site I (subdomain II A). Furthermore, Ir(III) complexes were found to dock within the apo-Tf binding site, including nearby tyrosine residues.

Highlights

  • There is a massive development in exploiting the medicinal properties of organometallic compounds in recent years, which have become an alternative to the clinically used anticancer drugs based on platinum

  • Is pentamethylcyclopentadienyl) with phosphines conjugated with fluoroquinolones as ligands, which were synthesized according to the literature procedure described by our group in previous publications (Scheme 1) [11,12,13,14]

  • All complexes were precisely characterized by selected methods, i.e., absorption and fluorescence spectroscopies, ESI-MS, NMR, and electrochemical techniques

Read more

Summary

Introduction

There is a massive development in exploiting the medicinal properties of organometallic compounds in recent years, which have become an alternative to the clinically used anticancer drugs based on platinum (e.g., cisplatin, carboplatin, nedaplatin). These organometallic complexes with novel mechanisms of action have the ability to broaden the spectrum approach to tumors, reduce side effects, and overcome drug resistance [1,2,3].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call